Metastatic Renal Cell Cancer Treated With Antiangiogenic Therapy Monitoring by 18F-FDG PET/CT
ABSTRACTRenal cell carcinoma (RCC) is resistant to chemotherapy and radiotherapy in most cases, and surgery is the preferred option in patients with local tough advanced disease. Even in metastatic RCC, patient survival has been reported to improve after surgery. Considering the importance of angiog...
Gespeichert in:
| Veröffentlicht in: | Clinical nuclear medicine 2015-11, Vol.40 (11), p.910-911 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 911 |
|---|---|
| container_issue | 11 |
| container_start_page | 910 |
| container_title | Clinical nuclear medicine |
| container_volume | 40 |
| creator | García Garzon, J.R Bassa, Pere Llinares, Elena Soler, Marina Moragas, Merce Riera, Eduard |
| description | ABSTRACTRenal cell carcinoma (RCC) is resistant to chemotherapy and radiotherapy in most cases, and surgery is the preferred option in patients with local tough advanced disease. Even in metastatic RCC, patient survival has been reported to improve after surgery. Considering the importance of angiogenesis in RCC pathogenesis, new inhibitors of vascular endothelial growth factor pathway show promising results. Imaging monitoring with F-FDG PET/CT may allow selecting the appropriateness and right time to implement these drugs, according to disease outcome. |
| doi_str_mv | 10.1097/RLU.0000000000000927 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1720453760</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1720453760</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2207-15124f7cea5cd27101463115b3c90fe50d75b7d808235008b46b7abcdabfaf0e3</originalsourceid><addsrcrecordid>eNp9kE1PwzAMhiMEgvHxDxDKkUs3J2mS9ojGBkhDIFTECVVp6m6Frh1JJrR_T9EAIQ74YF-e15YfQk4ZDBmkevQwexzC70q53iEDJoWKgPN0lwxAKBGlWvEDcuj9CwBTTMX75IArLrngckCebzEYH0yoLX3A1jR0jE3fTGvR0cyhCVjSpzos6EUbatPO626ObU9nC3RmtaG3XVuHztXtnBYbypJpNL28oveTbDTOjsleZRqPJ1_ziDxOJ9n4OprdXd2ML2aR5Rx0xCTjcaUtGmlLrhmwWAnGZCFsChVKKLUsdJlAwoUESIpYFdoUtjRFZSpAcUTOt3tXrntbow_5sva2f8S02K19zjSHWAqtoEfjLWpd573DKl-5emncJmeQf4rNe7H5X7F97OzrwrpYYvkT-jbZA8kWeO-agM6_Nut3dPkCTRMW_-_-AOKkgpA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1720453760</pqid></control><display><type>article</type><title>Metastatic Renal Cell Cancer Treated With Antiangiogenic Therapy Monitoring by 18F-FDG PET/CT</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>García Garzon, J.R ; Bassa, Pere ; Llinares, Elena ; Soler, Marina ; Moragas, Merce ; Riera, Eduard</creator><creatorcontrib>García Garzon, J.R ; Bassa, Pere ; Llinares, Elena ; Soler, Marina ; Moragas, Merce ; Riera, Eduard</creatorcontrib><description>ABSTRACTRenal cell carcinoma (RCC) is resistant to chemotherapy and radiotherapy in most cases, and surgery is the preferred option in patients with local tough advanced disease. Even in metastatic RCC, patient survival has been reported to improve after surgery. Considering the importance of angiogenesis in RCC pathogenesis, new inhibitors of vascular endothelial growth factor pathway show promising results. Imaging monitoring with F-FDG PET/CT may allow selecting the appropriateness and right time to implement these drugs, according to disease outcome.</description><identifier>ISSN: 0363-9762</identifier><identifier>EISSN: 1536-0229</identifier><identifier>DOI: 10.1097/RLU.0000000000000927</identifier><identifier>PMID: 26252325</identifier><language>eng</language><publisher>United States: Copyright Wolters Kluwer Health, Inc. All rights reserved</publisher><subject>Adult ; Angiogenesis Inhibitors - therapeutic use ; Carcinoma, Renal Cell - diagnostic imaging ; Carcinoma, Renal Cell - drug therapy ; Carcinoma, Renal Cell - pathology ; Female ; Fluorodeoxyglucose F18 ; Humans ; Kidney Neoplasms - diagnostic imaging ; Kidney Neoplasms - drug therapy ; Kidney Neoplasms - pathology ; Middle Aged ; Multimodal Imaging ; Neoplasm Metastasis ; Positron-Emission Tomography ; Radiopharmaceuticals ; Tomography, X-Ray Computed</subject><ispartof>Clinical nuclear medicine, 2015-11, Vol.40 (11), p.910-911</ispartof><rights>Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2207-15124f7cea5cd27101463115b3c90fe50d75b7d808235008b46b7abcdabfaf0e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26252325$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>García Garzon, J.R</creatorcontrib><creatorcontrib>Bassa, Pere</creatorcontrib><creatorcontrib>Llinares, Elena</creatorcontrib><creatorcontrib>Soler, Marina</creatorcontrib><creatorcontrib>Moragas, Merce</creatorcontrib><creatorcontrib>Riera, Eduard</creatorcontrib><title>Metastatic Renal Cell Cancer Treated With Antiangiogenic Therapy Monitoring by 18F-FDG PET/CT</title><title>Clinical nuclear medicine</title><addtitle>Clin Nucl Med</addtitle><description>ABSTRACTRenal cell carcinoma (RCC) is resistant to chemotherapy and radiotherapy in most cases, and surgery is the preferred option in patients with local tough advanced disease. Even in metastatic RCC, patient survival has been reported to improve after surgery. Considering the importance of angiogenesis in RCC pathogenesis, new inhibitors of vascular endothelial growth factor pathway show promising results. Imaging monitoring with F-FDG PET/CT may allow selecting the appropriateness and right time to implement these drugs, according to disease outcome.</description><subject>Adult</subject><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Carcinoma, Renal Cell - diagnostic imaging</subject><subject>Carcinoma, Renal Cell - drug therapy</subject><subject>Carcinoma, Renal Cell - pathology</subject><subject>Female</subject><subject>Fluorodeoxyglucose F18</subject><subject>Humans</subject><subject>Kidney Neoplasms - diagnostic imaging</subject><subject>Kidney Neoplasms - drug therapy</subject><subject>Kidney Neoplasms - pathology</subject><subject>Middle Aged</subject><subject>Multimodal Imaging</subject><subject>Neoplasm Metastasis</subject><subject>Positron-Emission Tomography</subject><subject>Radiopharmaceuticals</subject><subject>Tomography, X-Ray Computed</subject><issn>0363-9762</issn><issn>1536-0229</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1PwzAMhiMEgvHxDxDKkUs3J2mS9ojGBkhDIFTECVVp6m6Frh1JJrR_T9EAIQ74YF-e15YfQk4ZDBmkevQwexzC70q53iEDJoWKgPN0lwxAKBGlWvEDcuj9CwBTTMX75IArLrngckCebzEYH0yoLX3A1jR0jE3fTGvR0cyhCVjSpzos6EUbatPO626ObU9nC3RmtaG3XVuHztXtnBYbypJpNL28oveTbDTOjsleZRqPJ1_ziDxOJ9n4OprdXd2ML2aR5Rx0xCTjcaUtGmlLrhmwWAnGZCFsChVKKLUsdJlAwoUESIpYFdoUtjRFZSpAcUTOt3tXrntbow_5sva2f8S02K19zjSHWAqtoEfjLWpd573DKl-5emncJmeQf4rNe7H5X7F97OzrwrpYYvkT-jbZA8kWeO-agM6_Nut3dPkCTRMW_-_-AOKkgpA</recordid><startdate>201511</startdate><enddate>201511</enddate><creator>García Garzon, J.R</creator><creator>Bassa, Pere</creator><creator>Llinares, Elena</creator><creator>Soler, Marina</creator><creator>Moragas, Merce</creator><creator>Riera, Eduard</creator><general>Copyright Wolters Kluwer Health, Inc. All rights reserved</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201511</creationdate><title>Metastatic Renal Cell Cancer Treated With Antiangiogenic Therapy Monitoring by 18F-FDG PET/CT</title><author>García Garzon, J.R ; Bassa, Pere ; Llinares, Elena ; Soler, Marina ; Moragas, Merce ; Riera, Eduard</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2207-15124f7cea5cd27101463115b3c90fe50d75b7d808235008b46b7abcdabfaf0e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Carcinoma, Renal Cell - diagnostic imaging</topic><topic>Carcinoma, Renal Cell - drug therapy</topic><topic>Carcinoma, Renal Cell - pathology</topic><topic>Female</topic><topic>Fluorodeoxyglucose F18</topic><topic>Humans</topic><topic>Kidney Neoplasms - diagnostic imaging</topic><topic>Kidney Neoplasms - drug therapy</topic><topic>Kidney Neoplasms - pathology</topic><topic>Middle Aged</topic><topic>Multimodal Imaging</topic><topic>Neoplasm Metastasis</topic><topic>Positron-Emission Tomography</topic><topic>Radiopharmaceuticals</topic><topic>Tomography, X-Ray Computed</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>García Garzon, J.R</creatorcontrib><creatorcontrib>Bassa, Pere</creatorcontrib><creatorcontrib>Llinares, Elena</creatorcontrib><creatorcontrib>Soler, Marina</creatorcontrib><creatorcontrib>Moragas, Merce</creatorcontrib><creatorcontrib>Riera, Eduard</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical nuclear medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>García Garzon, J.R</au><au>Bassa, Pere</au><au>Llinares, Elena</au><au>Soler, Marina</au><au>Moragas, Merce</au><au>Riera, Eduard</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Metastatic Renal Cell Cancer Treated With Antiangiogenic Therapy Monitoring by 18F-FDG PET/CT</atitle><jtitle>Clinical nuclear medicine</jtitle><addtitle>Clin Nucl Med</addtitle><date>2015-11</date><risdate>2015</risdate><volume>40</volume><issue>11</issue><spage>910</spage><epage>911</epage><pages>910-911</pages><issn>0363-9762</issn><eissn>1536-0229</eissn><abstract>ABSTRACTRenal cell carcinoma (RCC) is resistant to chemotherapy and radiotherapy in most cases, and surgery is the preferred option in patients with local tough advanced disease. Even in metastatic RCC, patient survival has been reported to improve after surgery. Considering the importance of angiogenesis in RCC pathogenesis, new inhibitors of vascular endothelial growth factor pathway show promising results. Imaging monitoring with F-FDG PET/CT may allow selecting the appropriateness and right time to implement these drugs, according to disease outcome.</abstract><cop>United States</cop><pub>Copyright Wolters Kluwer Health, Inc. All rights reserved</pub><pmid>26252325</pmid><doi>10.1097/RLU.0000000000000927</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0363-9762 |
| ispartof | Clinical nuclear medicine, 2015-11, Vol.40 (11), p.910-911 |
| issn | 0363-9762 1536-0229 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1720453760 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adult Angiogenesis Inhibitors - therapeutic use Carcinoma, Renal Cell - diagnostic imaging Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - pathology Female Fluorodeoxyglucose F18 Humans Kidney Neoplasms - diagnostic imaging Kidney Neoplasms - drug therapy Kidney Neoplasms - pathology Middle Aged Multimodal Imaging Neoplasm Metastasis Positron-Emission Tomography Radiopharmaceuticals Tomography, X-Ray Computed |
| title | Metastatic Renal Cell Cancer Treated With Antiangiogenic Therapy Monitoring by 18F-FDG PET/CT |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T06%3A02%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Metastatic%20Renal%20Cell%20Cancer%20Treated%20With%20Antiangiogenic%20Therapy%20Monitoring%20by%2018F-FDG%20PET/CT&rft.jtitle=Clinical%20nuclear%20medicine&rft.au=Garc%C3%ADa%20Garzon,%20J.R&rft.date=2015-11&rft.volume=40&rft.issue=11&rft.spage=910&rft.epage=911&rft.pages=910-911&rft.issn=0363-9762&rft.eissn=1536-0229&rft_id=info:doi/10.1097/RLU.0000000000000927&rft_dat=%3Cproquest_cross%3E1720453760%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1720453760&rft_id=info:pmid/26252325&rfr_iscdi=true |